Qritive selected among the top 20 companies to participate in the prestigious MedTech Innovator Asia Pacific Accelerator 2024 program

Singapore, July 2, 2024 — MedTech Innovator, the world’s largest accelerator of medical technology companies, chose us from over 400 applicants for this year’s Asia Pacific program. This selection highlights our commitment to advancing medical technology and transforming patient care. We had the opportunity to join a cohort of innovators and engage with investors, business leaders, and industry professionals at the Innovator Summit 2024 in San Francisco on June 12-13. Our experience at the MedTech Innovator Summit 2024 in Mountain View, California, was enriching. The 2-day program included insightful content, activities, and connections. We appreciate the chance to meet and reconnect with many talented individuals who are transforming healthcare. Well done to the organizing team, our fellow members of #MTIAPAC, and all the participating startups. Thank you to MedTech Innovator and all the sponsors and partners for this opportunity. Together, we aim to drive the commercialization of life-changing technologies in the region and beyond.

About Qritive

Qritive, headquartered in Singapore with operations in the US and India, is transforming digital pathology through advanced AI-powered solutions that support cancer diagnosis and improve health outcomes.

By leveraging cutting-edge deep learning technology, Qritive supports pathologists in the interpretation of pathology assessments and enhances pathology workflows—enabling faster, more accurate diagnoses and reducing time to treatment.

Qritive is committed to empowering healthcare professionals around the world with tools that promote collaboration and high performance, regardless of complexity or distance.

Get in Touch

Want to learn more about our solutions or explore potential collaborations?

Visit www.qritive.com or contact us at info@qritive.com